Sign in

CIK 0001652130

  • Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
364785571
Phone
+1 857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Grant or award Director acquired 8,000 shares (grant or award)
  2. 4 Grant or award Director acquired 8,000 shares (grant or award)
  3. 4 Grant or award Director acquired 8,000 shares (grant or award)
  4. 4 Grant or award Director acquired 8,000 shares (grant or award)
  5. 4 Grant or award Director acquired 8,000 shares (grant or award)
  6. 4 Planned sale Director sold 265 shares at $8.50 ($2,253)
  7. 4 Open-market sale EVP, Chief Technical Officer sold 679 shares at $8.99 ($6,104)
  8. 4 Grant or award President and CEO acquired 136,000 shares (grant or award)
  9. 4 Grant or award EVP, Chief Financial Officer acquired 47,200 shares (grant or award)
  10. 4 Grant or award VP, Chief Accounting Officer acquired 14,000 shares (grant or award)
  11. 4 Grant or award EVP, Chief Medical Officer acquired 43,200 shares (grant or award)
  12. 4 Grant or award EVP, Chief Scientific Officer acquired 37,600 shares (grant or award)
  13. 4 Open-market sale EVP, General Counsel sold 2,572 shares at $8.99 ($23,122)
  14. 4 Planned sale Director sold 265 shares at $9.97 ($2,642)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale VP, Chief Accounting Officer sold 1,372 shares at $12.18 ($16,711)
  17. 4 Open-market sale EVP, General Counsel sold 7,074 shares at $12.18 ($86,161)
  18. 4 Open-market sale EVP, Chief Medical Officer sold 9,557 shares at $12.18 ($116,404)
  19. 4 Open-market sale EVP, Chief Business Officer sold 6,502 shares at $12.18 ($79,194)
  20. 4 Open-market sale President and CEO sold 26,807 shares at $12.18 ($326,509)

Page 3 of 18 · 353 filings